Last reviewed · How we verify
NCT04809935
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
Phase 4 trial testing 98% dehydrated alcohol in Cancer of Pancreas in 54 participants. Status unknown.
31 January 2024
Quick facts
| Lead sponsor | The University of Hong Kong |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 21 September 2020 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- 98% dehydrated alcohol — full drug profile →
- 19G EUSRA needle, Taewoong Medical, Korea
Conditions studied
- Cancer of Pancreas — all drugs for Cancer of Pancreas →
- Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
- Pain — all drugs for Pain →
- Cancer-Associated Pain — all drugs for Cancer-Associated Pain →
Sponsor
The University of Hong Kong
Who can join
18 and older, any sex, with Cancer of Pancreas or Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many cancer patients suffer from intractable pain and which is often suboptimally controlled by even strong opioid analgesics. Coeliac plexus neurolysis (CPN) is procedure which intended to permanently destroy the nociceptive pathway that transmits the pain caused by the tumour. It can be with different approaches, such as percutaneously guided by fluoroscopy, echo-endoscopically or surgically with endoscopic approach being the more popular one in many centers equipped with echo-endoscopic services. The effect of CPN has been well established by some retrospective series. The overall response rate to CPN ranges from 70-90%, however, the analgesic effect is limited and up to roughly around 3 months. It is believed that the short-lasting analgesic effect is related to incomplete neurolysis by absolute alcohol injection. Recently, radiofrequency ablation (RFA) of coeliac plexus has been introduced as another mode of CPN. So far, only one small single center randomized controlled trial (RCT) suggesting superior performance in favour to CPN using RFA. This result has to be validated and by a RCT with larger sample size. In addition, data concerning the quality of life (QOL) improvement and cost-effectiveness need to be further elucidated. Therefore, the aim of this study is to perform a RCT to look into these issues.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.
Bazeed AY, Day CM, Garg S. · · 2022 · cited 42× · PMID 36077794 · DOI 10.3390/cancers14174257 -
Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation.
Moond V, Maniyar B, Harne PS, Bailey-Lundberg JM, et al · · 2024 · cited 6× · PMID 39351436 · DOI 10.37349/etat.2024.00263
Verify or expand the search:
- PubMed search for NCT04809935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Pancreas
Currently open trials in the same condition.
- NCT06940778 — LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TU · active not recruiting
- NCT05485974 — A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation · Phase 1 · active not recruiting
- NCT06344507 — Iconographic Registry of Pancreatobiliary Endoscopy Procedures · recruiting
- NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
- NCT04677244 — Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level · NA · recruiting
Other The University of Hong Kong trials
Trials by the same sponsor.
- NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
- NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
- NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
- NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
- NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04809935 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
- Last refreshed: 22 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing